Advertisement

Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy

Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy

Eur J Ophthalmol 2012; 22(5): 792 - 798

Article Type: ORIGINAL ARTICLE

DOI:10.5301/ejo.5000118

Authors

Sofija P. Davidovic, Stanislava V. Nikolic, Nikola J. Curic, Slobodanka L.J. Latinovic, Dragan O. Draškovic, Velibor S. Cabarkapa, Zoran Z. Stošic

Abstract

Purpose. Avastin (bevacizumab) intravitreal injections are widely used for treatment of diabetic retinopathy. The aim of our study was to analyze effect of 1.25 mg of intravitreal Avastin on serum concentration of vascular endothelial growth factor (VEGF) in diabetic patients.  Methods. Participants were 10 diabetic patients on insulin therapy, without any other eye or systemic disease, and no kidney disfunction. Both eyes of diabetic patients were injected simultaneously with 1.25 mg of intravitreal Avastin, as a first step in treatment of nonproliferative diabetic retinopathy with clinically significant macular edema (4 patients), and of proliferative diabetic retinopathy (6 patients). Fluorescein angiography was performed prior to and laser therapy followed 1 month after Avastin treatment. VEGF concentration in patients serum was measured by ELISA technique: on the day of the Avastin administration, and 1, 7, and 28 days after intravitreal injection.  Results. In all analyzed participants, 24 hours after Avastin treatment, serum levels of VEGF were lower then basal (preinjection value). Maximal reduction of serum VEGF was noted on the 7th postoperative day. Twenty-eight days after, VEGF level in serum was raised, without completely reaching basal preoperative concentrations in most patients. Conclusions. Intravitreal injections of anti-VEGF drugs have an effect on decreasing systemic VEGF values. Rhythm of changes in serum VEGF concentrations and lowest detected concentration on the seventh postinjection day are according to pharmacokinetics of Avastin in serum and vitreous, reported by similar studies. The small number of patients involved in this pilot study implicates the need for further studies.

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36.00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Davidovic, Sofija P. [PubMed] [Google Scholar]
    University Eye Clinic, Clinical Center Vojvodina, Novi Sad - Serbia
  • Nikolic, Stanislava V. [PubMed] [Google Scholar]
    Center of Laboratory Medicine, Clinical Center Vojvodina, Novi Sad - Serbia
  • Curic, Nikola J. [PubMed] [Google Scholar]
    Center of Laboratory Medicine, Clinical Center Vojvodina, Novi Sad - Serbia
  • Latinovic, Slobodanka L.J. [PubMed] [Google Scholar]
    University Eye Clinic, Clinical Center Vojvodina, Novi Sad - Serbia
  • Draškovic, Dragan O. [PubMed] [Google Scholar]
    Institute for Forensic Medicine, Clinical Center Vojvodina, Novi Sad - Serbia
  • Cabarkapa, Velibor S. [PubMed] [Google Scholar]
    Center of Laboratory Medicine, Clinical Center Vojvodina, Novi Sad - Serbia
  • Stošic, Zoran Z. [PubMed] [Google Scholar]
    Center of Laboratory Medicine, Clinical Center Vojvodina, Novi Sad - Serbia

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.